Replies to post #28 on Seres Therapeutics Inc (MCRB)

[Paulieme]

July 29, 2016- "Currently, the analyst consensus on Seres Therapeutics is Strong Buy and the average price target is $46.50, representing a 445.8% upside." -According to The Fly, cowen & Co. analyst Ritu Baral reiterated a Buy rating on Seres Therapeutics (NASDAQ: MCRB) today. The company’s shares opened today at $8.52.


Ritu Baral, 4 star ranked analyst.

According to TipRanks.com, Baral is a 4-star analyst with an average return of 4.6% and a 44.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

http://www.analystratings.com/2016/07/29/seres-therapeutics-receives-a-buy-from-cowen-co-2/448028/